JP5422377B2 - 癌の処置および予防のための試薬および方法 - Google Patents

癌の処置および予防のための試薬および方法 Download PDF

Info

Publication number
JP5422377B2
JP5422377B2 JP2009502932A JP2009502932A JP5422377B2 JP 5422377 B2 JP5422377 B2 JP 5422377B2 JP 2009502932 A JP2009502932 A JP 2009502932A JP 2009502932 A JP2009502932 A JP 2009502932A JP 5422377 B2 JP5422377 B2 JP 5422377B2
Authority
JP
Japan
Prior art keywords
cells
cancer
thapsigargin
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535298A5 (enExample
JP2009535298A (ja
Inventor
カイバン アール． ニアジ，
シャールーズ ラビザデー，
デール イー． ブレデセン，
Original Assignee
ザ バック インスティテュート フォー エイジ リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ バック インスティテュート フォー エイジ リサーチ filed Critical ザ バック インスティテュート フォー エイジ リサーチ
Publication of JP2009535298A publication Critical patent/JP2009535298A/ja
Publication of JP2009535298A5 publication Critical patent/JP2009535298A5/ja
Application granted granted Critical
Publication of JP5422377B2 publication Critical patent/JP5422377B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009502932A 2006-03-27 2007-03-27 癌の処置および予防のための試薬および方法 Expired - Fee Related JP5422377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/389,695 US9107863B2 (en) 2006-03-27 2006-03-27 Reagents and methods for cancer treatment and prevention
US11/389,695 2006-03-27
PCT/US2007/007526 WO2007126787A2 (en) 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013170115A Division JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Publications (3)

Publication Number Publication Date
JP2009535298A JP2009535298A (ja) 2009-10-01
JP2009535298A5 JP2009535298A5 (enExample) 2011-05-12
JP5422377B2 true JP5422377B2 (ja) 2014-02-19

Family

ID=38533710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009502932A Expired - Fee Related JP5422377B2 (ja) 2006-03-27 2007-03-27 癌の処置および予防のための試薬および方法
JP2013170115A Expired - Fee Related JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013170115A Expired - Fee Related JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Country Status (8)

Country Link
US (4) US9107863B2 (enExample)
EP (2) EP2974738B1 (enExample)
JP (2) JP5422377B2 (enExample)
CN (1) CN101443036A (enExample)
AU (1) AU2007245169B2 (enExample)
CA (1) CA2647542A1 (enExample)
ES (2) ES2548435T3 (enExample)
WO (1) WO2007126787A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376495B2 (ja) 1992-08-18 2003-02-10 ソニー株式会社 接着剤の塗布方法及び接着治具
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
CZ300806B6 (cs) * 2007-07-18 2009-08-12 Ústav experimentální mediciny AV CR, v.v.i. Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy
BR112015023088A2 (pt) * 2013-03-15 2017-11-21 Genspera Inc método para preparar um composto, e, composto
EP2796137A1 (en) * 2013-04-22 2014-10-29 Universität des Saarlandes SERCA inhibitor and Calmodulin antagonist combination
CN112891354B (zh) * 2021-03-18 2022-10-21 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
JP2001010973A (ja) * 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
PL354997A1 (en) * 1999-09-25 2004-03-22 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
EP2128267A2 (en) * 2001-10-31 2009-12-02 Astellas Pharma Inc. Methods of evaluating phosphatase inhibitors
US20030235818A1 (en) * 2002-04-08 2003-12-25 Vsevolod Katritch Immunogenic peptides, and method of identifying same
AU2003301526A1 (en) 2002-10-25 2004-05-13 University Of Connecticut Health Center Immunotherapy of cancer through controlled cell lysis
ES2469670T3 (es) * 2003-11-30 2014-06-18 Yeda Research And Development Co., Ltd. Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention

Also Published As

Publication number Publication date
EP2004219A2 (en) 2008-12-24
AU2007245169A1 (en) 2007-11-08
ES2655909T3 (es) 2018-02-22
WO2007126787A3 (en) 2008-10-23
US9885704B2 (en) 2018-02-06
JP2014028815A (ja) 2014-02-13
US8895031B2 (en) 2014-11-25
US20100278874A1 (en) 2010-11-04
JP2009535298A (ja) 2009-10-01
US9107863B2 (en) 2015-08-18
CA2647542A1 (en) 2007-11-08
US20160069864A1 (en) 2016-03-10
EP2004219A4 (en) 2010-06-30
EP2974738B1 (en) 2017-11-15
AU2007245169B2 (en) 2012-05-24
US20180128816A1 (en) 2018-05-10
JP5712257B2 (ja) 2015-05-07
WO2007126787A2 (en) 2007-11-08
US20070224207A1 (en) 2007-09-27
ES2548435T3 (es) 2015-10-16
EP2004219B1 (en) 2015-09-16
CN101443036A (zh) 2009-05-27
EP2974738A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP5712257B2 (ja) 癌の処置および予防のための試薬および方法
JP6222749B2 (ja) 医薬組成物及びその使用
Son et al. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy
JP3976742B2 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2011516471A (ja) 腫瘍性疾患を治療するための組成物および方法
TW202245808A (zh) 用於治療癌症之治療性ｒｎａ
JP2023538077A (ja) がんの治療方法
Chikh et al. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles
WO2019202473A1 (en) Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade
US20230233474A1 (en) Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
JP5397692B2 (ja) 悪性黒色腫抗原の発現上昇剤及びその用途
Tancharoen et al. The role of water channel aquaporin 3 in the mechanism of TNF‐α‐mediated proinflammatory events: Implication in periodontal inflammation
KR20220042944A (ko) 종양미세환경을 이용한 뇌종양 치료 또는 치료제의 스크리닝 방법
US20180117176A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
Oresta Immunogenic cell death as a new mechanism of action of the chemotherapeutic drug mitomycin C in bladder cancer
WO2023056337A1 (en) Tlr8 agonist for modulating immune response
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan
Colombo p50 Nuclear Factor-B Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130820

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131125

R150 Certificate of patent or registration of utility model

Ref document number: 5422377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees